Clinical Haematology Department - Princess Alexandra Hospital

Contact: Adam Stoneley
Phone: 61 7 3176 2111
 

Site Information

The Department of Clinical and Laboratory Haematology is a tertiary referral centre for the study and management of haematological malignancies. The department continues to develop clinical programmes in leukaemias, lymphomas and myeloma with multidisciplinary clinics in these diseases. The department has one of the largest lymphoma clinics in the southern hemisphere. Because of its focus on the diagnosis and treatment of leukaemia, and lymphoma, the group has developed unique expertise in blood cancers and has a leading role in raising standards at national and international levels. Research is carried out at three levels - basic, translational and clinical - with the focus being on improving patient outcomes. The department actively participates in all phases of clinical trials with some trials being initiated from this Unit and now with national and international participation. The staff have been invited, by the National Health and Medical Research Council (NHMRC) and Australian Cancer Network (ACN), to participate in producing guidelines for management of Hodgkin’s, Non-Hodgkin’s Lymphomas and Transplant related Lymphomas. The focus of the translational research is on gene expression profiling in chronic lymphocytic leukaemia and detecting minimal disease in acute myeloid leukaemia (AML) and lymphoma not detectable with current technology. By utilising modern biological techniques, methods have been developed to detect and quantify extremely small amount of disease. The unit is recognised as a leader in this field. Ability to detect very small amount of disease enables further treatment to be given or for treatment to begin earlier. Furthermore, the treatment as a result can be ‘individualised’ and should result in higher cure rates.

Key Research Focus - As of the 31st of October 2011, 25 of the active clinical trials originated by leading clinicians in the field from cancer collaborative groups. Another 24 of the clinical trials were sponsored by the pharmaceutical industry and another 8 studies were created and initiated by investigators locally.

  • Phase II
  • Phase III
  • Dose Escalation
  • Dose Expansion
  • Pharmacokinetics
  • Pharmacodynamics
  • Paediatric
  • Adult
  • Geriatric
  • Familar with advanced disease

Contact

Adam Stoneley

61 7 3176 2111

Divison of Cancer Services

Princess Alexandra Hospital

Princess Alexandra Hospital

Princess Alexandra Hospital

Oncology Outpatient Department, 2nd Floor

Ipswich Road

Woolloongabba

Brisbane

Queensland

4102

Australia

http://www.health.qld.gov.au/pahospital

Staffing

Specialists on Staff

Haematologist

Number of Principal Investigators: 11

Number of Sub-Investigators: As above

Number of Study Coordinators: 7

Number of Data Managers: As above

Number of Ethics/Study Start-Up Specialists: 1

Outsourced monitoring and/or start-up activities: No

Year Started Clinical Research: 1991

Number of Clinical Trials Run Per Year: Approximately 31 clinical trials are available each year

Number of Participants Consented Per Year: Approximately 58 participants recruited per year

Facilities

Trial Equipment

  • Fridge with temperature logging
  • Freezer with temperature logging
  • Centrifuge
  • High-Speed Centrifuge
  • Refrigerated Centrifuge
  • Secure Drug Storage
  • Secure Document Storage
  • Archiving Facilities

Support Services

  • Dispensing Pharmacy
  • Compounding Pharmacy
  • Pathology Laboratory
  • Radiology

Participant Services

  • Participant Facilities for Long Day Visits (Greater than 7hours)
  • In-Patient Beds for Overnight Visits
  • In-Patient Beds and Facilities for Multi-day Visits

I.T. Services

  • High Speed Internet Access
  • Individual Email Accounts
  • Able to facilitate Remote Monitoring
  • Familar with eCRF's
  • Familar with IVRS
  • In-House I.T. Help-Desk

Imaging

  • General X-ray
  • Fluroscopy
  • Mammography
  • DEXA (Bone Densitometry) Scan
  • Ultrasound
  • CT (Computed Tomography) Scan
  • MRI (Magnetic Resonance Imaging)
  • PET (Positron Emission Tomography) Scan
  • Nuclear Medicine
  • Endoscope

Imaging Facilities Related to Clinical Research: Our site does not have specifically dedicated imaging facilites but we have a very health relationship with the hospital's Department of Diagnostic Radiology who are very experienced in performing assessments for research and have no issues in scheduling investigations to follow trial protocols.

Sampling

  • Tissue
  • Tumour/Tumor
  • Skin Punch
  • Hair Follicle
  • Buccal Mucosa
  • Blood Serum
  • Blood Plasma
  • DNA

Local Labs

  • Hematopathology
  • Molecular Diagnositics
  • Molecular Pre-Screening
  • Rare cell detection
  • Immunoassays
  • Molecular pathology
  • DNA alteration testing
  • mRNA expression analysis
  • Protein Expression
  • Metabolite Profiling

Study Start-Up

Site Religious and Cultural Considerations:
No

Participant Religious and Cultural Considerations:
No

Potential Language Barriers:
No specific language barriers. We do not require PICF translations. Translators are available upon request.

Tissue Banking & Exploratory Analysis:
Yes. Tissue blocks are rarely allowed to be sent off-site but slides and other sera are defiently acceptable.

Non-Returnable and Identifiable Tissue Banking Issues:
Yes, samples are rarely expected to be returned.

Ethics Committee:
For multi-centre studies we submit to a central coordinating authority who can allocate to a range of ethics committees, but when given the option our site prefers to use our local ethics committee which has a high level of expertise and local knowledge.

Ethics Committee Meetings:
Monthly

Site Research Governance:
No

Are Ethics and Research Governance made in parallel:
Yes

Standardised Contracts:
Yes, we use the Medicines Australia templates.

Standardised Indemnities:
Yes, we use the Medicines Australia templates.

Interdepartmental Sign-Off:
Yes, all studies are reviewed internally at departmental trial review meetings before the Cancer Trials Unit seeks approval to coommit resources from other stakeholders.

Start-Up Timeline:
Approximately 3 to 4 months but this gap is steadily reducing.

Investigators

Dr Robert Bird

Position at Site: Director of Haematology, Pathology Queensland

Research Interests: ITP, TTP, APML

Contact Person: Adam Stoneley

Contact Person Position: Research Unit Coordinator

Contact Phone: 61 7 3176 2111

Contact Email:

Dr Peter Wood

Position at Site: Consultant Haematologist

Research Interests: NHL, Myeloma

Contact Person: Adam Stoneley

Contact Person Position: Research Unit Coordinator

Contact Phone: 61 7 3176 5054

Contact Email:

Associate Professor Andrew Perkins

Position at Site: Consultant Haematologist

Research Interests: Myelofibrosis

Contact Person: Adam Stoneley

Contact Person Position: Research Unit Coordinator

Contact Phone: 61 7 3176 5054

Contact Email:

Dr Peter Mollee

Position at Site: Consultant Haematologist

Research Interests: Myeloma, Amyloidosis

Contact Person: Adam Stoneley

Contact Person Position: Research Unit Coordinator

Contact Phone: 61 7 3176 5054

Contact Email:

Associate Professor Devinder Gill

Position at Site: Director of Clinical Haematology

Research Interests: CLL, DLBCL

Contact Person: Adam Stoneley

Contact Person Position: Research Unit Coordinator

Contact Phone: 61 7 3176 5054

Contact Email:

Dr Matthew Hourigan

Position at Site: Consultant Haematologist

Contact Person: Adam Stoneley

Contact Person Position: Research Unit Coordinator

Contact Phone: 61 7 3176 5054

Contact Email:

Dr Sally Mapp

Position at Site: Consultant Haematologist

Research Interests: ALL, PCNSL

Contact Person: Adam Stoneley

Contact Person Position: Research Unit Coordinator

Contact Phone: 61 7 3176 5054

Contact Email:

Dr Anthony Mills

Position at Site: Consultant Haematologist

Research Interests: CML, MDS, PNH

Contact Person: Adam Stoneley

Contact Person Position: Research Unit Coordinator

Contact Phone: 61 7 3176 5054

Contact Email:

Associate Professor Maher Gandhi

Position at Site: Consultant Haematologist

Research Interests: Hodgkin Lymphoma, NHL

Contact Person: Adam Stoneley

Contact Person Position: Research Unit Coordinator

Contact Phone: 61 7 3176 2111

Contact Email:

Dr Helen Wordsworth

Position at Site: Consultant Haematologist

Contact Person: Adam Stoneley

Contact Person Position: Research Unit Coordinator

Contact Phone: 61 7 3176 5054

Contact Email:

Associate Professor Paula Marlton

Position at Site: Consultant Haematologist

Research Interests: AML, CLL, NHL, Myeloma

Contact Person: Adam Stoneley

Contact Person Position: Research Unit Coordinator

Contact Phone: 61 7 3176 5054

Contact Email:

Network Membership

Princess Alexandra Hospital (PA Hospital)

Division of Cancer Services - Princess Alexandra Hospital (QLD)

The Princess Alexandra Hospital has a large, highly developed cancer service operating in a sophisticated modern hospital with an expert staff. There is a strong tradition of basic and clinical research with a record of success in research translation. For the Cancer Collaborative Group, Clinical Trials form a significant part of the research basis upon which the departments, centres and units work. It is therefore very important for the Cancer Collaborative Group to create a sustainable future for Clinical Trials. The Cancer Collaborative Group was formed to foster and further enhance the research capability, foster internal and externa...